Deerfield Management Company, L.P. (Series C) Adaptive Biotechnologies Corp Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.34 - $3.96 $134,676 - $227,913	57,554 Added 88.16%	122,841 $444,000
Q1 2024 May 15, 2024	BUY	$2.88 - $4.8 $188,026 - $313,377	65,287 New	65,287 $209,000
Q3 2019 Nov 14, 2019	SELL	$30.31 - $53.51 $2.12 Million - $3.75 Million	-70,000 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$40.3 - $48.3 $2.82 Million - $3.38 Million	70,000 New	70,000 $3.38 Million

Others Institutions Holding ADPT

# of Institutions

206

Shares Held

142M

Call Options Held

68.8K

Put Options Held

42.5K

Viking Global Investors LP

30M
Shares

$235 Million
0.59% of portfolio
Rubric Capital Management LP New York, NY

14.4M
Shares

$113 Million
2.05% of portfolio
Black Rock Inc. New York, NY

11.7M
Shares

$91.4 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

10.6M
Shares

$83.4 Million
0.0% of portfolio
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl

9.42M
Shares

$73.9 Million
0.49% of portfolio

View Full List

About Adaptive Biotechnologies Corp

Ticker ADPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 142,872,992
Market Cap $1.12B
Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...

More about ADPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account